Ultragenyx cuts 20% staff, ends two rare disease programs after trial failure

Ultragenyx announced layoffs of ~20% and discontinuation of two rare disease drug programs following another failed study. This signals a strategic contraction and likely negative market reaction, though the specific financial impact remains unquantified.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works